Cargando…
Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
BACKGROUND: This study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills (QYDP) in chronic heart failure (CHF) via a long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) axis. Here, the mechanism of action of the lncRNA terminal differ...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745534/ https://www.ncbi.nlm.nih.gov/pubmed/36524095 http://dx.doi.org/10.21037/jtd-22-1322 |
_version_ | 1784849173672099840 |
---|---|
author | Chen, Lei Pan, Lihua Zhang, Yuansheng Chen, Yuewu Su, Yangshen Luo, Ying Wu, Zengfan Zheng, Wanling Cai, Shikang Liu, Xianxia Wu, Xiaoyan |
author_facet | Chen, Lei Pan, Lihua Zhang, Yuansheng Chen, Yuewu Su, Yangshen Luo, Ying Wu, Zengfan Zheng, Wanling Cai, Shikang Liu, Xianxia Wu, Xiaoyan |
author_sort | Chen, Lei |
collection | PubMed |
description | BACKGROUND: This study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills (QYDP) in chronic heart failure (CHF) via a long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) axis. Here, the mechanism of action of the lncRNA terminal differentiation-induced non-coding RNA (TINCR), miR-193b-3p, and RAR-related orphan receptor A (RORA) mRNA was analyzed in an angiotensin (Ang) II-induced H9C2 cardiomyocyte hypertrophy model treated with QYDP. METHODS: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to analyze the gene expression changes of lncRNA, miRNA, and mRNA in H9C2 induced by QYDP on Ang II. The Gene Expression Omnibus (GEO) was used to analyze differentially expressed genes (DEGs) potentially affecting CHF progression. Cell Counting Kit-8 (CCK-8) was used to analyze the effect of QYDP on the proliferation of H9C2, RNA pull-down was used to analyze the binding of lncRNA and miRNA, and dual luciferase was used to analyze the targeting of miRNA and lncRNA or mRNA. RESULTS: Ang II induced TINCR and RORA downregulation, miR-193b-3p upregulation, and hypertrophy in the H9C2 cardiomyocytes, which were alleviated by QYDP. In contrast, TINCR inhibition reversed the effects of QYDP by increasing miR-193b-3p expression and downregulating RORA expression. According to subsequent double luciferase and RNA pull-down experiments, TINCR adsorbed miR-193b-3p by acting as a competitive endogenous RNA sponge and miR-193b-3p directly targeted RORA. Lastly, we showed that the Ang-II-induced inhibition of TINCR and RORA expression and promotion of cardiac hypertrophy were both reversed by a TINCR overexpression plasmid (ov-TINCR), whereas the effects of ov-TINCR were suppressed by a miR-193b-3p mimic. CONCLUSIONS: Administration of QYDP improves Ang II-induced H9C2 cardiomyocyte hypertrophy and increase cell proliferation rate through the TINCR/miR-193b-3p/RORA axis. |
format | Online Article Text |
id | pubmed-9745534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-97455342022-12-14 Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis Chen, Lei Pan, Lihua Zhang, Yuansheng Chen, Yuewu Su, Yangshen Luo, Ying Wu, Zengfan Zheng, Wanling Cai, Shikang Liu, Xianxia Wu, Xiaoyan J Thorac Dis Original Article BACKGROUND: This study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills (QYDP) in chronic heart failure (CHF) via a long non-coding RNA (lncRNA)-microRNA (miRNA)-messenger RNA (mRNA) axis. Here, the mechanism of action of the lncRNA terminal differentiation-induced non-coding RNA (TINCR), miR-193b-3p, and RAR-related orphan receptor A (RORA) mRNA was analyzed in an angiotensin (Ang) II-induced H9C2 cardiomyocyte hypertrophy model treated with QYDP. METHODS: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to analyze the gene expression changes of lncRNA, miRNA, and mRNA in H9C2 induced by QYDP on Ang II. The Gene Expression Omnibus (GEO) was used to analyze differentially expressed genes (DEGs) potentially affecting CHF progression. Cell Counting Kit-8 (CCK-8) was used to analyze the effect of QYDP on the proliferation of H9C2, RNA pull-down was used to analyze the binding of lncRNA and miRNA, and dual luciferase was used to analyze the targeting of miRNA and lncRNA or mRNA. RESULTS: Ang II induced TINCR and RORA downregulation, miR-193b-3p upregulation, and hypertrophy in the H9C2 cardiomyocytes, which were alleviated by QYDP. In contrast, TINCR inhibition reversed the effects of QYDP by increasing miR-193b-3p expression and downregulating RORA expression. According to subsequent double luciferase and RNA pull-down experiments, TINCR adsorbed miR-193b-3p by acting as a competitive endogenous RNA sponge and miR-193b-3p directly targeted RORA. Lastly, we showed that the Ang-II-induced inhibition of TINCR and RORA expression and promotion of cardiac hypertrophy were both reversed by a TINCR overexpression plasmid (ov-TINCR), whereas the effects of ov-TINCR were suppressed by a miR-193b-3p mimic. CONCLUSIONS: Administration of QYDP improves Ang II-induced H9C2 cardiomyocyte hypertrophy and increase cell proliferation rate through the TINCR/miR-193b-3p/RORA axis. AME Publishing Company 2022-11 /pmc/articles/PMC9745534/ /pubmed/36524095 http://dx.doi.org/10.21037/jtd-22-1322 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Chen, Lei Pan, Lihua Zhang, Yuansheng Chen, Yuewu Su, Yangshen Luo, Ying Wu, Zengfan Zheng, Wanling Cai, Shikang Liu, Xianxia Wu, Xiaoyan Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis |
title | Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis |
title_full | Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis |
title_fullStr | Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis |
title_full_unstemmed | Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis |
title_short | Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis |
title_sort | qishen yiqi dropping pills improve cardiomyocyte hypertrophy via the lncrna tincr/mir-193b-3p/rora axis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745534/ https://www.ncbi.nlm.nih.gov/pubmed/36524095 http://dx.doi.org/10.21037/jtd-22-1322 |
work_keys_str_mv | AT chenlei qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT panlihua qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT zhangyuansheng qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT chenyuewu qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT suyangshen qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT luoying qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT wuzengfan qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT zhengwanling qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT caishikang qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT liuxianxia qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis AT wuxiaoyan qishenyiqidroppingpillsimprovecardiomyocytehypertrophyviathelncrnatincrmir193b3proraaxis |